Bevacizumab in Combination with Capecitabine/Irinotecan or Capecitabine/Oxaliplatin is Effective and Safe as First-Line Therapy for Metastatic Colorectal Cancer: a Randomized Phase II Study of the Aio Colorectal Study Group

Trial Profile

Bevacizumab in Combination with Capecitabine/Irinotecan or Capecitabine/Oxaliplatin is Effective and Safe as First-Line Therapy for Metastatic Colorectal Cancer: a Randomized Phase II Study of the Aio Colorectal Study Group

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2013

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Nov 2010 New trial record
    • 27 Oct 2010 Results were presented at the 18th United European Gastroenterology Week.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top